Here are the obesity drug hopefuls vying to unseat Ozempic and Zepbound
Insatiable demand for weight-loss drugs has made the market so hot that any positive mention of a potential therapy can send a firm’s stock surging — even if those treatments may still be years away.
After Amgen Inc.’s chief executive officer, Robert Bradway, said he was “very encouraged” by early results of an experimental obesity shot, the stock on Friday leapt 16%, its biggest gain since 2009. That’s despite no new data being released on the drug — which is in mid-stage trials — and before the approval process has even begun.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
.jpg&w=384&q=75)
